Payment overview · 2025
General Payments
$1,141.23
31 reported records · 16 companies
Healthcare provider profile · identity verified
Ryan Christopher Francis, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAFAYETTE, LA · NPI 1306367834
Verified facts
What the public records show
CMS Open Payments records show Ryan Christopher Francis, FNP-C received $1,141.23 in general payments during 2025 across 31 reported records.
Ardelyx, Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $221.18 | 19.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $207.05 | 18.1% | 6 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $161.45 | 14.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $158.72 | 13.9% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $121.69 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.53 | 4.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.47 | 3.3% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $29.60 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.62 | 2.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.93 | 2.0% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $18.53 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.74 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.25 | 1.5% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $17.21 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.51 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.75 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,141.23 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $221.18 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $161.45 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $151.04 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $130.53 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $121.69 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.01 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
191 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 723 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 153 |
| Losartan Potassium | Losartan Potassium | 703 | 139 |
| Gabapentin | Gabapentin | 523 | 114 |
| Metformin Hcl | Metformin Hcl | 390 | 87 |
| Januvia | Sitagliptin Phosphate | 322 | 60 |
| Omeprazole | Omeprazole | 320 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 71 |
| Glipizide | Glipizide | 274 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 60 |
| Lisinopril | Lisinopril | 231 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 38 |
| Carvedilol | Carvedilol | 226 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 46 |
| Fenofibrate | Fenofibrate Nanocrystallized | 201 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 195 | 41 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 191 | 25 |
| Trulicity | Dulaglutide | 191 | 30 |
| Trazodone Hcl | Trazodone Hcl | 188 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 155 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 40 |
| Jardiance | Empagliflozin | 146 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 35 |
| Potassium Chloride | Potassium Chloride | 131 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 31 |
| Meloxicam | Meloxicam | 121 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 30 |
| Furosemide | Furosemide | 120 | 37 |
| Famotidine | Famotidine | 119 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 109 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 25 |
| Prednisone | Prednisone | 108 | 73 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 100 | 13 |
| Pregabalin | Pregabalin | 100 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 22 |
| Naproxen | Naproxen | 98 | 37 |
| Montelukast Sodium | Montelukast Sodium | 96 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 15 |
| Mounjaro | Tirzepatide | 76 | 13 |
| Alprazolam | Alprazolam | 75 | 14 |
| Clonidine Hcl | Clonidine Hcl | 75 | 20 |
| Linzess | Linaclotide | 74 | 15 |
| Buprenorphine Hcl | Buprenorphine Hcl | 69 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Allopurinol | Allopurinol | 66 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | suppressed |
| Simvastatin | Simvastatin | 60 | 19 |
| Ezetimibe | Ezetimibe | 59 | 24 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 57 | 19 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 17 |
| Tramadol Hcl | Tramadol Hcl | 54 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 13 |
| Myrbetriq | Mirabegron | 52 | 11 |
| Ibuprofen | Ibuprofen | 49 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 24 |
| Levetiracetam | Levetiracetam | 46 | 12 |
| Eliquis | Apixaban | 44 | 11 |
| Unithroid | Levothyroxine Sodium | 42 | suppressed |
| Mupirocin | Mupirocin | 40 | 24 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 12 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Methimazole | Methimazole | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Incassia | Norethindrone | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,141.23 · 31 records | Ardelyx, Inc. | Auvelity, BRIXADI, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Kerendia, Ohtuvayre, PURIFIED CORTROPHIN GEL, QULIPTA, SUBLOCADE, Sunosi, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VRAYLAR, Xelstrym | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error